• Hollywall owns the rights to and music recordings of more than 17,500 songs, in addition to the rights to 29 video games and a film
• As of December 2019, the company’s music library was valued at $146 million
• The music industry has witnessed an upsurge in music catalog acquisitions by investment and management firms and leading music companies
• Hollywall is led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments

The 2010s saw an upsurge in music catalog acquisitions, a trend that only accelerated into the 2020s. Describing this “catalog acquisition frenzy,” a January 2021 Rolling Stone Magazine article observed that even investment and management firms and Wall Street companies had entered into the music business by buying rights to famous musicians’ creative works (https://ibn.fm/UCEZK). “Right now, the gorillas in this jungle include Larry Mestel’s Primary Wave and Merck Mercuriadis’s Hipgnosis Songs Fund, two investment and management firms: in 2021 alone, the latter company acquired copyrights and/or income streams from Neil Young, Lindsey Buckingham of Fleetwood Mac, Shakira, and Jimmy Iovine,” reads the article. “This isn’t the first time in recent memory that Wall Street mammoths have gotten involved in the inner workings of the music business,” the article continues. “In 2016, BlackRock (a company with $7.8 trillion in assets under management) led a $300 million investment into Primary Wave – money that was subsequently spent on legendary music catalogs like Bob Marley’s.” Leading music companies such as Warner Music Group and Universal Music Group have also splurged tens of millions of dollars on music catalogs. The logic behind such acquisitions is simple. Firstly, master recordings earn revenue through various avenues, namely sampling, streaming and purchases/downloads, public broadcast, and use in television, film, and commercials. Secondly and according to a 2020 Variety Magazine article, “Publishing assets are currently running at multiples well over 12 with master rights slightly lower but increasing in value… In five to 10 years, it might be 20x – the value continues to rise” (https://ibn.fm/OBLpT). Notably, the market multiple analysis is a valuation approach that applies an EBITDA multiple or Net Publisher’s Share (“NPS”)/Net Label’s Share (“NLS”) multiple based on recent precedent acquisitions. It is used to derive a catalog’s implied market value (https://ibn.fm/Mjfe2). The increasing interest in music catalogs and their projected rise in value bodes well for Hollywall Entertainment (OTC: HWAL), an entertainment, media, infrastructure, telecommunication, technology, and broadcasting company that operates through various subsidiaries. The company, which serves some of the finest creators, writers, developers, and music artisans of our time by offering a business solution and distribution platform that maximizes a global audience reach, wholly owns an extensive music and entertainment library. Hollywall’s asset portfolio includes copyrights, legal rights, trademarks, and master recordings of over 17,500 songs, one of the largest master recording libraries globally. This library features hit songs from the likes of Michael Jackson, Elvis Presley, The Jacksons 5, Marvin Gaye, Dolly Parton, Frank Sinatra, The Who, Bob Marley, Quincy Jones, James Taylor, and more. In addition, HWAL owns the source code, rights, and trademarks of 29 video games and the rights to a film titled ‘The Elvis I Knew.’ With a fair value of about $146 million as of December 31, 2019, according to an intangible asset valuation prepared by Sun Business Valuation and available on the HWAL’s website (https://ibn.fm/3SdFe), Hollywall’s master recordings are only bound to increase in value as time progresses, positioning HWAL for growth well into the future. Led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments, Hollywall is favorably poised as one of the entertainment industry’s most exciting companies. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms
• The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation on psychedelics. Delic announced that the Company’s Co-founder and Chief Executive Officer, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference, held in an entirely virtual format from January 10-13, 2022. In addition to carrying out one-on-one meetings throughout the course of the conference, Mr. Stang made a corporate presentation on Delic Corp’s expansion strategy and overall industry outlook for the general public. H.C. Wainwright & Co., a full-service investment bank dedicated to providing investment banking, equity research, sales and trading, as well corporate access and strategic advisory services, celebrated 150 years of service in 2018. The firm has gained a well-deserved reputation for its innovative conference line-up over the years, having recently hosted events on topics as varied and diverse as psychedelics, mining, precision oncology, hepatitis B, ophthalmology, cryptocurrencies, blockchain technology and applications, and many more. The H.C. Wainwright Bioconnect Conference, hosted by former FDA commissioner Dr Scott Gottlieb, has sought to bring together a carefully curated collection of cutting-edge biopharmaceutical firms alongside institutional investors, private equity firms, venture capitalists, and industry executives. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/Bu2g4). With the sector on the cusp of broad-based legalization, the psychedelic wellness market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/jFEPL). Delic has sought to capitalize on the sector’s growth as well as rising demand for psychedelic products and services through the expansion of its proprietary Ketamine Wellness Centers (“KWC”), the largest chain of psychedelic wellness clinics in the country, with 15 more clinics opening in the next 18 months. Delic has also looked to expand its footprint within the sector through its other related businesses, which include Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the world’s largest psychedelic wellness event; as well as media platforms, Reality Sandwich and Delic Radio. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Company marked host of major milestones and accomplishments in 2021
• Approvals, licenses, expansions and growth all essential pieces of Cybin success
• CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022

As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. “2021 was an exciting year for Cybin,” said Cybin CEO Doug Drysdale. “We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months.” And that’s just the beginning for the emerging leader in the psychedelics industry. The company points to several key highlights this past year as proof positive it is on the right road to psychedelic success. Ranking at the top of 2021 milestones were the notice of allowance awarded from the U.S. Patent and Trademark Office for Cybin’s CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for the company’s cofunded investigator-initiated phase 2 clinical trial. Using the EMBARK psychedelic facilitator training program, the trial is designed to evaluate psychedelic-assisted psychotherapy to treat frontline clinicians experiencing COVID-related distress. In addition, company leaders confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding CYBN’s lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder. Cybin also announced positive CYB003 data showing significant advantages compared to oral psilocybin for the treatment of mental health disorders, including a 50% reduction in variability, a 50% reduction in dose, a 50% shorter time to onset and nearly double brain penetration. Other 2021 highlights for Cybin included receiving a grant for a psychedelic treatment clinic at Lenox Hill Hospital, part of the largest healthcare system in New York State, to benefit underserved communities; being granted a schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab, which will allow the company to expand its internal R&D capabilities; receiving approval from the FDA for its investigational new drug application to proceed with a company-sponsored feasibility study using the Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics; and the completion of 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. There were many more 2021 highlights for Cybin, which expanded operations into Europe and was the first psychedelic company to list on the NYSE American market. “Driven by promising and differentiating preclinical data, our innovative operational and R&D pipeline platforms expect to support four first-in-human clinical studies in 2022, which we hope will progress our proprietary psychedelic development candidates CYB003 and CYB004 closer toward potential approval for treating depression and addiction disorders,” Drysdale stated. “We believe 2022 will be a truly transformative year for Cybin.” Cybin is a leading ethical biopharmaceutical company on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development
• He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year
• Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market
• Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap digital health platform

Josh Bartch, the Co-Founder, Chairman, and Chief Executive Officer (“CEO”) of Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), recently appeared on The Bell2BellPodcast, a platform meant to highlight key organizations, leaders and entrepreneurs who are leaving a mark in their respective industries. Mr. Bartch briefly shared his background, leading up to co-founding Mydecine, along with the goals for the company for the new year. Of note was Mydecine’s phased approach, which Bartch noted is integral to the company’s operations, along with its future. “Mydecine Innovations Group…is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a blueprint or starting point and then making several improvements for what we call second-generation psychedelic molecules for the treatment of a number of indications,” Bartch noted (https://ibn.fm/kLsnW). So far, Mydecine addresses two lead indications- smoking cessation and PTSD. In 2021, the company partnered with Johns Hopkins University (“JHU”) for further research on smoking cessation and has so far made some significant strides in PTSD treatment. In addition, its phased approach, which entails understanding the imperfections of initial formulations and then modifying them to make them more effective, has already set the company apart from its peers. As a result, the first generation of products is already proving significantly better than what is currently available in the market. “For smoking cessation, for instance, you’re looking at no good solutions currently available,” noted Mr. Bartch. “You have Chantix, which was recently recalled for a cancer-causing carcinogen…Even before, when it was still available on the shelf, this is a blockbuster drug doing $1.2 billion per year with efficacy data in the single digits at 12 months,” he added. With what Mydecine is offering, Bartch noted, early-stage trials have proven to be way better than what was available in the market. Efficacy data has shown upwards of 80% in six months and 67% at 12 months, all attributed to its phased approach. “Through our phased approach, we take that first generation, look at imperfections and make improvements- things in the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc.,” Bartch reckoned. Going into 2022, Mr. Bartch was keen to note that Mydecine will start two clinical trials- a smoking cessation study and a PTSD Phase 2a study. He also noted the company’s commitment to focusing more on novel compound production and getting them to clinics around the country, which will also be accompanied by publishing pre-clinical results following the studies carried out so far. 2022 will also be the year when Mydecine commercializes its Mindleap digital health platform, as it focuses on growing the number of its users and further improving its offering. To listen to the whole podcast, please visit https://ibn.fm/JQwe2 For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Mineral property exploration company StraightUp Resources enters 2022 with a new CEO, the tailwind from a new OTCQB Market listing, DTC Eligibility, and encouraging reports on its properties and neighboring properties owned by other companies
• As Americans shift their focus from COVID policies to inflationary pressures and other economic matters, many investors are mulling the appeal of precious metals as a safe haven
• StraightUp holds a mine in the historically productive Bullfrog mining district in Southern Nevada
• The company also holds options for five potentially productive greenbelt sites in Ontario, which the company is assessing

As Americans weary of COVID-19 pandemic restrictions and worry more about the economy and inflations’ effects on their personal finances (https://ibn.fm/zvg2o), many investors are considering a move toward precious metals as a safe haven (https://ibn.fm/PpcPM). Despite recent negative perceptions about gold values, “The December-January period is historically very strong for bullion, which has gained in 8 out of the last 10 Januaries,” a senior investment analyst at brokerage XM recently stated (https://ibn.fm/agG3q). StraightUp Resources (CSE: ST) (OTCQB: STUPF), a company dedicated to acquiring and exploring precious metals resources, is optimistic about the potential of the precious metals market in light of the uncertainty in economic forces at play in the world today. The Canadian company is focusing most of its attention on five projects it has optioned in Ontario’s greenbelt region. The Ferdinand, RLX North and RLX South, Belanger and Bear Head Gold projects sit astride 21,087 hectares (52,107 acres) of potential productivity in a zone already known for gold output topping 30 million ounces. Airborne magnetic surveys (“MAG”) have been completed on three of StraightUp’s properties, and some ground exploration has begun. The company is also enthused about a United States mine property acquired last year in the historically gold-productive Bullfrog region around Beatty, Nev. — particularly in light of news that South African gold major AngloGold Ashanti has upped its investment in the premier mining jurisdiction by buying out Corvus Gold’s shares in order to acquire other Bullfrog region properties (https://ibn.fm/lMWus). StraightUp Resources is similarly encouraged by the potential for stockholder optimism after Kinross Gold Corp. announced last month a definitive agreement with Great Bear Resources Ltd. to buy the company and its holdings, including Red Lake District property neighboring StraightUp’s Ferdinand Gold Project in Ontario (https://ibn.fm/4g505). The company’s international aspirations also led it to contemplate the potential acquisition a silver mine and processing plant in Peru through a right of exclusivity agreement (“ROE”) for all outstanding shares in Premier Silver Corp. that the company announced in October. The ROE had an expiration date in late December if it was not fulfilled, however, and StraightUp ended the year without completing any new acquisitions or business relationships that had not been previously announced, according to a recent monthly progress report (erroneously dated 2021) (https://ibn.fm/mxDyP). In order to build on the company’s potential going into 2022, experienced entrepreneur and economic geologist Rod Husband was named the company’s new CEO in December while former CEO Mark Brezer tightened his focus on his duties as president and director (https://ibn.fm/k6qwp). “We are excited to have Mr. Husband’s calibre of leadership and operational experience on board, especially during this phase of the Company’s growth and expansion into international markets. This appointment strengthens management and brings a new layer of expertise to the team,” Brezer stated in the announcement. The company upgraded to the OTCQB Venture Market in the United States to improve its access to investors, and on Jan. 10 announced a non-brokered private placement to raise additional funding (https://ibn.fm/k74QQ). For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• In August, GreenBox celebrated a monumental milestone when it processed over $1 billion in transaction volume for all of 2021
• GreenBox’s year-to-date processing volume grew to $1.4 billion as of September 30, 2021
• The company reported $8 million in revenue and $5.6 million in gross profit in Q3 2021
• GreenBox appointed Paul Levine as CEO and Co-Founder of Coyni stablecoin spinoff company, Robert Houghton as CTO, and Jacqueline Reynolds as CMO
• The company’s management hosted a year-end update call on December 9

Approximately eight months after GreenBox POS (NASDAQ: GBOX) released its Generation 3 (“Gen3”) technology, which expanded and expedited the process of onboarding, monitoring, and controlling merchant portfolios in its proprietary blockchain-based platform, the company crossed a significant milestone – the processing of more than $1 billion in transaction volume in 2021. The milestone represented about five times the total processing volume recorded in 2020 (https://ibn.fm/IwNLS). Attributable to the Gen3 technology, expansion of its ISO and agent network, and the acquisitions of ChargeSavvy and Northeast Merchant Services, the monumental milestone demonstrated GreenBox’s successful development and deployment of its one-of-a-kind blockchain ledger-based payment processing technology. These factors would again play a significant role in growing the transaction volume figures even further as detailed in a November 11 news release detailing the financial results for the three months ended September 30, 2021 (“Q3 2021”) (https://ibn.fm/GzOeP). GreenBox noted it had processed a quarterly record of $540 million, which contributed to a year-to-date volume of $1.4 billion as of September 30, 2021. Notably, this Q3 2021 transaction volume had grown roughly 1,400% compared to a similar period a year earlier. Other key highlights included a 163% year-over-year (“YoY”) increase in quarterly net revenue from $3.0 million in Q3 2020 to $8.0 million in Q3 2021. Sequentially, the net revenues increased by 26% quarter over quarter (“QoQ”) from $6.4 million recorded in Q2 2021. At the same time, gross profit in Q3 2021 stood at $5.6 million (69.5% of total revenue), compared to $1.2 million (39.6% of total revenue) in Q3 2020 and $5.1 million (79.3% of total revenue) in Q2 2021. Additionally, the company fortified its balance sheet upon securing a $100 million convertible note financing. The fund will go toward supporting its acquisition strategy, adding money to its Coyni stablecoin revolver to grow it up to $25 million, and additional technology development. GreenBox also engaged in revenue sharing and licensing cooperation with Transact Europe enabling it to leverage key licensing assets and recognize processing volume. “Our third quarter of 2021 was instrumental in building the foundation for 2022 and beyond. We continued to successfully execute on our long-term growth strategy of quickly scaling our processing volume while accumulating licensing assets through select acquisitions and partnerships,” commented GreenBox CEO Fredi Nisan. “Despite all GreenBox has accomplished in the last 18 months, we are still just in the early innings of scaling our technology. We remain confident in our long-term strategy and are well positioned to capitalize on the opportunity at hand.” Fredi underlined that the company expects to grow its processing volumes and exceed its initial 2021 guidance of $1.85 billion. Further, GreenBox expects 2021 reported revenue of at least $28 million and adjusted net income of at least $8 million. The third quarter also saw several additions to the company’s management team. GreenBox appointed Paul Levine, a technology innovator and former President of Planet Payment, as CEO and Co-Founder of the Coyni stablecoin spinoff company (“SpinCo”), as it lays the groundwork for the eventual public offering of Coyni. Additionally, the company hired Robert Houghton as the Chief Technology Officer. In this role, Robert will lead GreenBox’s payment technology roadmap as well as ensure efficient integration of acquisitions. On November 16, the company announced the appointment of marketing guru Jacqueline B. Reynolds as its new Chief Marketing Officer (“CMO”). A world-class global marketer, she has launched massive campaigns while working with household names such as Coca-Cola (NYSE: KO), McDonald’s (NYSE: MCD), Verizon (NYSE: VZ), Walmart (NYSE: WMT), L’Oréal, Xbox,  7-Eleven, and other Fortune 500 companies. She has also held senior leadership positions at global brands, top agencies, and media companies, spearheading award-winning programs with international partners. “As CMO, Jacqueline will lead all marketing strategy, including the development of GreenBox’s brand positioning, along with a communications plan to relevantly connect with customers and investors, focused across a variety of platforms,” explains the November 16 news release. Paul Levine and Jacqueline Reynolds joined several other key members of the company’s management, including GreenBox Chairman Ben Errez and Fredi Nisan, in a year-end corporate update call hosted on December 9 (https://ibn.fm/YrkxB). A recording of the call is available via https://ibn.fm/tVbrz (registration required), with a transcript available here https://ibn.fm/kihii. GreenBox is an emerging financial technology enterprise leveraging proprietary blockchain security and token technology to develop customized payment solutions. Guided by the mission to build compliant cutting edge blockchain ledger tokenized payment solutions for the diverse, evolving, and dynamic global market, the company operates along four pillars – card-issuing, payment processing, Coyni stablecoin, and banking-as-a-service. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX

• SPYR’s Applied MagiX seeks to leverage the large and loyal Apple following to establish its brand in the Apple Ecosystem
• The global smart home market is set to grow at a 15.75% CAGR over the next 5 years, rising to a value of $187 billion per annum by 2025
• SPYR Inc purchased subsidiary, Applied MagiX, to gain access to the smart home market as well as the Apple HomeKit product ecosystem
• As of 2021, Applied MagiX had launched 5 Apple-compatible products with plans to launch a proprietary line of products in the coming future

The Apple ecosystem is second-to-none. Apple has built a fiercely loyal consumer base through its products and services – ranging from Apple computers, peripherals, and iPhones, to services including, Apple News, Apple Fitness+, Apple Arcade and Apple Music. As an indicator of Apple’s significant and long-standing following, the company recently revealed that its App Store had connected with over 600 million people per week across 175 countries, enabling the App Store to generate over $260 billion in cumulative sales since its launch in 2008. Meanwhile, the 2021 holiday season saw App Store customers spend more than ever before between Christmas Eve and New Year’s Eve, driving double-digit growth relative to 2020 (https://ibn.fm/NAYiS). SPYR (OTCQB: SPYR), dba SPYR Technologies, is a technology company which, through its wholly owned subsidiary Applied MagiX Inc., develops and sells Apple(R)-ecosystem-compatible products, seeking to capitalize on the Apple consumer base through product offerings including devices and accessories specifically built on Apple’s HomeKit framework(R). Applied MagiX is a registered Apple developer and reseller. The global smart home market has made its mark as one of the fastest growth segments within the consumer market today, with the sector expected to generate revenue upwards of $104 billion in 2021. That figure is set to grow further still, rising to an annual total of $187 billion by 2025, with a 15.75 percent CAGR over the five-year interim (https://ibn.fm/rFHBu). In late 2020 and after witnessing the stunning growth within the sector, Denver-based SPYR Inc. opted to acquire Californian IoT company, Applied MagiX, with the acquisition propelling SPYR into the multi-billion-dollar smart home industry, and perhaps more critically, giving them entry into the Apple HomeKit smart home market (https://ibn.fm/HBGfJ). Having already begun generating sales and revenue through its partnerships with online retail giants Amazon, Walmart and eBay, SPYR’s Applied MagiX revealed plans to release a proprietary range of products designed to complement and work in conjunction with the Apple HomeKit system. Meanwhile and in the interim, the company has centred its offering around a range of white-labelled Apple HomeKit, Apple CarPlay, and Apple Watch products and accessories drawn from several trusted technology partners, thereby enabling Applied Magix to both generate revenues immediately, whilst simultaneously building an active customer base to introduce their own-branded product range to upon the latter’s release. SPYR and Applied MagiX launched their initial product range in April 2021, with a focus on five key consumer products – the MagixDrive Wireless CarPlay adapter; the HomeKit Secure Video Camera with iCloud Storage; the Multipurpose Sensor with Alarm; the Environment and Motion Sensor; and the Window and Door Contact Sensor. Apple has increasingly sought to combine its product offering as part of their holistic offering which includes iCloud+, thus introducing its home services and hardware to its millions of customers around the globe. With Apple set to become a dominant player within the global smart home sector, SPYR Inc and Applied MagiX look well placed to capitalize on the sector’s spectacular growth rate going forward. For more information, visit the company’s website at www.Spyr.com. NOTE TO INVESTORS: The latest news and updates relating to SPYR are available in the company’s newsroom at https://ibn.fm/SPYR

To give you the most comprehensive conference experience, Talent Acquisition Week 2022 pulls together sourcing, recruiting, and employer branding methods. Start the year off right with the most up-to-date solutions and trends to help you boost your talent acquisition strategy and position your company as a sought-after player in today’s employment market. Key Details

• Social Recruiting Strategies Conference #SRSC
• Employer Branding Strategies Conference #EBrandCon
• Talent Sourcing Strategies Summit

The forthcoming Talent Acquisition Week Conference will be held in a totally digital format on January 24-28, 2022, by the Global Strategic Management Institute, a cutting-edge conference production firm focused on fostering disruptive innovation. Talent Acquisition Week combines sourcing, recruiting, and employer branding tactics into a single event, allowing guests to participate in virtual networking rooms, ask questions, watch live lectures, and network one-on-one with colleagues from across the world. Why Should You Attend? The next Talent Acquisition Week aims to help the Talent Acquisition (“TA”) community apply new tactics, tools, and technology in order to advance their corporate playbooks. Over 50 presentations will be offered by renowned TA practitioners, and attendees will discover the most up-to-date and relevant recruiting, branding, and sourcing techniques while also hearing how businesses have overcome obstacles that TA processes confront on a regular basis. In addition to the live presentations, the Talent Acquisition Week will provide attendees with the opportunity to network with their human resources peers from across the country, allowing conference delegates to share their experiences and learn about new recruitment strategies with peers from across the country and around the world in a single seamless virtual forum. Andrew Gadomski, Managing Director of Aspen Analytics, will give the opening comments at this year’s event. Over the duration of the conference, there will be a series of live 30-minute presentations on the agenda. Stryker will present “How Intelligence Can Support Talent Acquisition and Your Brand,”, Waterford.Org will present “Using Data to Make Hiring Decisions”, Fountain will present “Leveraging Digital Transformation to Drive Your Talent Acquisition Strategy,” and Shaker Recruitment Marketing will present “Two Words That Will Make Your Employer Brand Diverse & Inclusive.” For more information, please visit https://ibn.fm/NPUrO.

The demand for detailed and accessible scientific knowledge has never been greater, as both consumers and HCPs struggle to adjust to life during COVID while aiming for a brighter future. Your medical affairs team must upskill and stay relevant now more than ever as consumers receive information through new media. DGE’s 5th Digital Strategy & Innovation for Medical Affairs Summit will take place February 7-9th 2022 and is the industry’s largest and most significant event for converting your medical affairs department into one that implements progressive policies and prioritizes patient care. In the digital age, this training will help you identify best practices for providing value to both internal and external stakeholders. Key Points

• Boost your competitiveness by improving your data literacy.
• Using innovative digital tactics, provide the greatest possible treatment and outcomes for patients.
• Ensure that your teams are up to date on emerging trends while avoiding unneeded fads.
• A vibrant, engaging community that places a premium on creativity at all levels.
• The most important industry event on the subject – with a proven interactive platform!

The information presented at the Digital Strategy & Innovation for Medical Affairs Summit will assist your company in staying current and transforming its medical affairs department. Learn how to implement progressive policies, promote patient centricity, and figure out how to demonstrate value to internal and external stakeholders in the digital age. The Digital Strategy & Innovation for Medical Affairs Summit is a place where individuals and companies can come together to solve problems and network with one another. Register to take part in an interactive seminar that will help you find best practices for establishing a digital strategy. Reasons To Attend The COVID epidemic has ushered in massive changes to which both patients and HCPs are adjusting. The demand for relevant, timely, and exact scientific data is stronger than ever before. The need of the hour is for medical affairs departments to undergo a thorough makeover by implementing new policies and emphasizing patient-centricity, demonstrating value to both internal and external stakeholders in the digital age. Medical practitioners can join their growing community of interactive participants who can understand the ins and outs of the digital revolution by attending this online conference. Industry executives, health providers, and policymakers will gather throughout the conference to discuss potential for innovation, improved accessibility and efficiency, and the digitization of healthcare that the pandemic has sparked. They will also examine and share their perspectives on the issues faced by medical professionals in adjusting to new technologies, as well as the post-COVID environment. For more information visit https://ibn.fm/xYnCR

• RWB marked 2021 with strategic acquisitions, with the most notable of them being Acreage Holdings Inc. and a 45,000 square foot greenhouse in Apopka, Florida
• These strategic investments would see the company steadily grow its revenue, marking a 93% year-over-year growth by Q3
• The year also marked notable appointments, including Ryan Costello and Colby De Zen, both into the company’s Board of Directors
• RWB is confident that the foundations laid down in 2021 will play a vital role in the company’s growth in 2022, as well as creating shareholder value

Since its inception, Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has remained focused on being a torchbearer, leading a new frontier in American cannabis. Accordingly, its operations have been defined by adhering to the highest ethical, manufacturing, educational, branding, and employment standards available in the industry. These factors have allowed it to set itself apart from other players in the cannabis space. Over the years, RWB has entered strategic brand acquisitions and partnerships to expand its market presence and position, and become one of the key players in the United States cannabis market. This would be one of the company’s highlights for the 2021 calendar year, kicking off with the acquisition of Acreage Holdings Inc. Later in the year, RWB would also mark other notable purchases, including a 45,000 square foot greenhouse in Apopka, Florida (https://ibn.fm/eYzkX). In December, RWB settled CAD$5.1 million debt and refinanced the CAD$12.8 million principal amount of its vendor take-back note to acquire all the issued and outstanding shares of Acreage Florida, Inc. This would mark the close of RWB’s 2021 list of acquisitions which, its management is confident, will be integral to growing its market share and presence in the new year (https://ibn.fm/Md1xP). Strategic investments for the company in 2021 paid off significantly. In Q1 2021, it posted a 14.5% increase in adjusted sales from the previous quarter (“Q4 2020”) (https://ibn.fm/itQJR). In addition, Q2 would mark a 13% increase in revenue over Q1 2021, with Q3 posting a 93% year-over-year increase in revenue, its biggest jump yet (https://ibn.fm/CeQOc). The company attributed this growth to the additional building blocks laid down over the year, as it works towards being even more profitable as time progresses. “In the third quarter, we made excellent progress in laying additional building blocks in our core operating states of Florida, Michigan, and California to become more vertically integrated where it will be most profitable. This will help drive increased revenue and margins for the company,” noted Brad Rogers, RWB’s Chairman and Chief Executive Officer (“CEO”). 2021 would also mark key appointments at RWB, starting with Ryan Costello’s appointment to the Board of Directors. In addition, the company also brought Colby De Zen, a renowned strategic investor, to its Board of Directors. These appointments would be integral to RWB’s growth and its representation within the United States market. Going into 2022, RWB is confident that the foundations laid down over the 2021 calendar year will play a vital role in the company’s growth and creating shareholder value. It has also been vocal about being asset-light and brand-rich, a strategy driven by supporting its brands most profitably. So far, it has put teams in place to help its plan in the different states it operates, a move that it believes will pay off in this new year. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF